Department of Emergency Intensvie Care Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu Province, China.
Medicine (Baltimore). 2021 Jan 22;100(3):e24085. doi: 10.1097/MD.0000000000024085.
: Fulminant myocarditis has a sudden onset and rapid progress, which can easily cause multiple organ failure. Acute kidney injury is a common complication. ECMO (extracorporeal membrane oxygenation) and CRRT (continuous renal replacement therapy) have been used in the treatment of fulminant myocarditis, but the combination of the 2 has an impact on the prognosis. There is still a big controversy. Therefore, the purpose of this randomized controlled trial is to evaluate the nursing effect and long-term efficacy and safety of ECMO combined with CRRT in the treatment of fulminant myocarditis.
: This is a prospective randomized controlled trial to study the effectiveness and safety of ECMO combined with CRRT in the treatment of fulminant myocarditis. Approved by the clinical research ethics committee of our hospital. Patients were randomly assigned to 1 of 2 treatment options: 1. ECMO combined with CRRT group and 2. ECMO group. Observation indicators include: basic vital signs, laboratory indicators, echocardiographic changes, complications, and outcomes. SPSS 25.0 (Chicago, IL) version statistical software package was used to analyze the data.
: This study will evaluate the nursing effect and long-term efficacy and safety of ECMO combined with CRRT in the treatment of fulminant myocarditis. The results of this experiment will provide clinical evidence for the treatment of fulminant myocarditis with ECMO and CRRT.
: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.
: DOI 10.17605/OSF.IO/PAQBZ.
暴发性心肌炎起病急骤、进展迅速,容易引发多脏器功能衰竭,急性肾损伤是其常见的并发症。ECMO(体外膜肺氧合)和 CRRT(连续性肾脏替代治疗)已应用于暴发性心肌炎的治疗,但二者联合对预后的影响存在争议。因此,本随机对照试验旨在评估 ECMO 联合 CRRT 治疗暴发性心肌炎的护理效果及远期疗效和安全性。
本研究是一项前瞻性随机对照试验,研究 ECMO 联合 CRRT 治疗暴发性心肌炎的有效性和安全性。本研究经我院临床研究伦理委员会批准。患者被随机分配到以下 2 种治疗方案中的 1 种:1. ECMO 联合 CRRT 组;2. ECMO 组。观察指标包括:基本生命体征、实验室指标、超声心动图变化、并发症和结局。采用 SPSS 25.0(芝加哥,IL)版统计软件包分析数据。
本研究将评估 ECMO 联合 CRRT 治疗暴发性心肌炎的护理效果及远期疗效和安全性。该实验的结果将为 ECMO 和 CRRT 联合治疗暴发性心肌炎提供临床依据。
不会公开个人信息。本系统评价也不会危及参与者的权利。本研究无需伦理批准。研究结果可能发表在同行评议的期刊上,或在相关会议上传播。
OSF 注册号:DOI 10.17605/OSF.IO/PAQBZ。